ARTICLE | Product R&D

Epizyme's mantle piece

Epizyme's next first-in-class histone methyltransferase cancer compound

January 15, 2015 8:00 AM UTC

Epigenetic modulation notched another target last month when Epizyme Inc. announced a preclinical compound against PRMT5 - an arginine methyltransferase - that shows activity in mouse models of mantle cell lymphoma. The next step is to discover what other cancers involve the target, and the biotech is hoping its partner GlaxoSmithKline plc will help it mine that landscape.

The enzyme is one of over 20 histone methyltransferases (HMTs) known to drive abnormal gene regulation and tumor growth...